Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer

Molecular Therapy

Volumn 17, Issue 3, 2009, Pages 430-438

  Mahdy, Ayman E M ^a   Cheng, Joseph C ^a   Li, Jun ^a   Elojeimy, Saeed ^a   Meacham, William D ^a   Turner, Lorianne S ^a   Bai, Aiping ^a   Gault, Christopher R ^a   McPherson, Alex S ^a   Garcia, Nicole ^a   Beckham, Thomas H ^a   Saad, Antonio ^a   Bielawska, Alicja ^a   Bielawski, Jacek ^a   Hannun, Yusuf A ^a   Keane, Thomas E ^a   Taha, Mohhammed I ^b   Hammouda, Hisham M ^b   Norris, James S ^a   Liu, Xiang ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Assiut University Faculty of Medicine   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ACID CERAMIDASE; CASPASE 3; CASPASE 7; CERAMIDE DERIVATIVE; DOXORUBICIN; ENZYME INHIBITOR; LCL 385; PACLITAXEL; SMALL INTERFERING RNA; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CLONOGENIC ASSAY; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PROSTATE CANCER; RADIOSENSITIVITY; RADIOSENSITIZATION; RECEPTOR UPREGULATION; TUMOR; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 61649091570     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.281     Document Type: Article

References (50)

1. Mangar, SA, Huddart, RA, Parker, CC, Dearnaley, DP, Khoo, VS and Horwich, A (2005). Technological advances in radiotherapy for the treatment of localised prostate cancer. Eur J Cancer 41: 908-921.
2. Peschel, RE and Colberg, JW (2003). Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 4: 233-241.
3. Hanks, GE, Hanlon, AL, Epstein, B and Horwitz, EM (2002). Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 54: 427-435.
4. Ward, JF (1988). DNA damage produced by ionizing radiation in mammalian cells: Identities, mechanisms of formation, and reparability. Prog Nucleic Acid Res Mol Biol 35: 95-125.
5. Allan, DJ (1992). Radiation-induced apoptosis: Its role in a MADCaT (mitosis-apoptosis-differentiation-calcium toxicity) scheme of cytotoxicity mechanisms. Int J Radiat Biol 62: 145-152.
6. Ogretmen, B and Hannun, YA (2004). Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4: 604-616.
7. Kolesnick, R and Fuks, Z (2003). Radiation and ceramide-induced apoptosis. Oncogene 22: 5897-5906.
8. Vit, JP and Rosselli, F (2003). Role of the ceramide-signaling pathways in ionizing radiation-induced apoptosis. Oncogene 22: 8645-8652.
9. Kimura, K, Markowski, M, Edsall, LC, Spiegel, S and Gelmann, EP (2003). Role of ceramide in mediating apoptosis of irradiated LNCaP prostate cancer cells. Cell Death Differ 10: 240-248.
10. Nava, VE, Cuvillier, O, Edsall, LC, Kimura, K, Milstien, S, Gelmann, EP et al. (2000). Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res 60: 4468-4474.
11. Hara, S, Nakashima, S, Kiyono, T, Sawada, M, Yoshimura, S, Iwama, T et al. (2004). p53-Independent ceramide formation in human glioma cells during γ-radiation-induced apoptosis. Cell Death Differ 11: 853-861.
12. Verheij, M, Bose, R, Lin, XH, Yao, B, Jarvis, WD, Grant, S et al. (1996). Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380: 75-79.
13. Mu, Z, Hachem, P and Pollack, A (2005). Antisense Bcl-2 sensitizes prostate cancer cells to radiation. Prostate 65: 331-340.
14. Chmura, SJ, Nodzenski, E, Kharbanda, S, Pandey, P, Quintans, J, Kufe, DW et al. (2000). Down-regulation of ceramide production abrogates ionizing radiation-induced cytochrome c release and apoptosis. Mol Pharmacol 57: 792-796.
15. Santana, P, Pena, LA, Haimovitz-Friedman, A, Martin, S, Green, D, McLoughlin, M et al. (1996). Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86: 189-199.
16. Bruno, AP, Laurent, G, Averbeck, D, Demur, C, Bonnet, J, Bettaieb, A et al. (1998). Lack of ceramide generation in TF-1 human myeloid leukemic cells resistant to ionizing radiation. Cell Death Differ 5: 172-182.
17. Alphonse, G, Bionda, C, Aloy, MT, Ardail, D, Rousson, R and Rodriguez-Lafrasse, C (2004). Overcoming resistance to gamma-rays in squamous carcinoma cells by poly-drug elevation of ceramide levels. Oncogene 23: 2703-2715.
18. Samsel, L, Zaidel, G, Drumgoole, HM, Jelovac, D, Drachenberg, C, Rhee, JG et al. (2004). The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 58: 382-393.
19. Haimovitz-Friedman, A, Kan, CC, Ehleiter, D, Persaud, RS, McLoughlin, M, Fuks, Z et al. (1994). Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 180: 525-535.
20. Chmura, SJ, Nodzenski, E, Beckett, MA, Kufe, DW, Quintans, J and Weichselbaum, RR (1997). Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res 57: 1270-1275.
21. Chmura, SJ, Mauceri, HJ, Advani, S, Heimann, R, Beckett, MA, Nodzenski, E et al. (1997). Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. Cancer Res 57 4340-4347.
22. Liao, WC, Haimovitz-Friedman, A, Persaud, RS, McLoughlin, M, Ehleiter, D, Zhang, N et al. (1999). Ataxia telangiectasia-mutated gene product inhibits DNA damage-induced apoptosis via ceramide synthase. J Biol Chem 274: 17908-17917.
23. Kolesnick, R (2002). The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 110: 3-8.
24. Norris, JS, Bielawska, A, Day, T, El-Zawahri, A, ElOjeimy, S, Hannun, Y et al. (2006). Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: A status report. Cancer Gene Ther 13: 1045-1051.
25. Seelan, RS, Qian, C, Yokomizo, A, Bostwick, DG, Smith, DI and Liu, W (2000). Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer 29: 137-146.
26. Saad, AF, Meacham, WD, Bai, A, Anelli, V, Elojeimy, S, Mahdy, AE et al. (2007). The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther 6: 1455-1460.
27. Liu, X, Elojeimy, S, El-Zawahry, AM, Holman, DH, Bielawska, A, Bielawski, J et al. (2006). Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther 14: 637-646.
28. Liu, X, Zeidan, YH, Elojeimy, S, Holman, DH, El-Zawahry, AM, Guo, GW et al. (2006). Involvement of sphingolipids in apoptin-induced cell killing. Mol Ther 14: 627-636.
29. Holman, DH, Turner, LS, El-Zawahry, A, Elojeimy, S, Liu, X, Bielawski, J et al. (2008). Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 61: 231-242.
30. Hannun, YA and Linardic, CM (1993). Sphingolipid breakdown products: antiproliferative and tumor-suppressor lipids. Biochim Biophys Acta 1154: 223-236.
31. Tannock, IF, de Wit, R, Berry, WR, Horti, J, Pluzanska, A, Chi, KN et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.
32. Petrylak, DP, Tangen, CM, Hussain, MH, Lara, PN Jr, Jones, JA, Taplin, ME et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520.
33. Kumar, P, Perrotti, M, Weiss, R, Todd, M, Goodin, S, Cummings, K et al. (2004). Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol 22: 1909-1915.
34. Sanfilippo, NJ, Taneja, SS, Chachoua, A, Lepor, H and Formenti, SC (2008). Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer. J Clin Oncol 26: 2973-2978.
35. Sui, M, Dziadyk, JM, Zhu, X and Fan, W (2004). Cell cycle-dependent antagonistic interactions between paclitaxel and gamma-radiation in combination therapy. Clin Cancer Res 10: 4848-4857.
36. Liebmann, J, Cook, JA, Fisher, J, Teague, D and Mitchell, JB (1994). Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol). Int J Radiat Oncol Biol Phys 29: 559-564.
37. Ingram, ML and Redpath, JL (1997). Subadditive interaction of radiation and Taxol in vitro. Int J Radiat Oncol Biol Phys 37: 1139-1144.
38. Stromberg, JS, Lee, YJ, Armour, EP, Martinez, AA and Corry, PM (1995). Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines. Cancer 75: 2262-2268.
39. Geard, CR and Jones, JM (1994). Radiation and taxol effects on synchronized human cervical carcinoma cells. Int J Radiat Oncol Biol Phys 29: 565-569.
40. Bowen, C, Spiegel, S and Gelmann, E (1998). Radiation-induced apoptosis mediated by retinoblastoma protein. Cancer Res 58: 3275-3281.
41. Algan, O, Stobbe, CC, Helt, AM, Hanks, GE and Chapman, JD (1996). Radiation inactivation of human prostate cancer cells: The role of apoptosis. Radiat Res 146: 267-275.
42. Li, WX and Franklin, WA (1998). Radiation- and heat-induced apoptosis in PC-3 prostate cancer cells. Radiat Res 150: 190-194.
43. Kolesnick, R, Haimovitz-Friedman, A and Fuks, Z (1994). The sphingomyelin signal transduction pathway mediates apoptosis for tumor necrosis factor, Fas, and ionizing radiation. Biochem Cell Biol 72: 471-474.
44. Kyprianou, N, King, ED, Bradbury, D and Rhee, JG (1997). bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 70: 341-348.
45. Chachisvilis, M, Zhang, YL and Frangos, JA (2006). G protein-coupled receptors sense fluid shear stress in endothelial cells. Proc Natl Acad Sci USA 103: 15463-15468.
46. Charles, AG, Han, TY, Liu, YY, Hansen, N, Giuliano, AE and Cabot, MC (2001). Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother Pharmacol 47: 444-450.
47. Bielawska, A, Bielawski, J, Szulc, ZM, Mayroo, N, Liu, X, Bai, A et al. (2008). Novel analogs of D-e-MAPP and B13. Part 2: Signature effects on bioactive sphingolipids. Bioorg Med Chem 16: 1032-1045.
48. Dagan, A, Wang, C, Fibach, E and Gatt, S (2003). Synthetic, non-natural sphingolipid analogs inhibit the biosynthesis of cellular sphingolipids, elevate ceramide and induce apoptotic cell death. Biochim Biophys Acta 1633: 161-169.
49. Pettus, BJ, Baes, M, Busman, M, Hannun, YA and Van Veldhoven, PP (2004). Mass spectrometric analysis of ceramide perturbations in brain and fibroblasts of mice and human patients with peroxisomal disorders. Rapid Commun Mass Spectrom 18: 1569-1574.
50. Zeidan, YH, Pettus, BJ, Elojeimy, S, Taha, T, Obeid, LM, Kawamori, T et al. (2006). Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor-{alpha}-induced PGE2 production. J Biol Chem 281: 24695-24703.